Quality of life with a chronic inflammatory disease

Lipum AB (publ) is a clinical phase biopharmaceutical company specializing in the discovery and development of new treatments for chronic inflammatory diseases. The drug candidate SOL-116 is a humanized monoclonal antibody being evaluated to provide safer and more effective treatment by blocking a previously overlooked target molecule in the immune system, the Bile Salt-Stimulated Lipase (BSSL). SOL-116 is in clinical phase with compelling preclinical data for rheumatoid arthritis (RA). Lipum is also evaluating other inflammatory diseases with significant unmet medical needs.

Lipum’s office and a laboratory reside within Uminova Science Park in Umeå. Development work is conducted with support from contracted consultants with specialist expertise in various aspects of drug development, as well as support from scientific advisors. Contract Research Organizations (CROs) are engaged for preclinical and clinical studies both nationally and internationally. Production of the SOL-116 antibody and formulation for use in clinical trials is also carried out by contracted external partners. Lipum also has scientific collaborations with the Cardiovascular Research Centre (CVRC) at Örebro University and researchers at the Karolinska Institute (Department of Medicine, division of Rheumatology).

The company’s discovery has gained international attention and received a significant Horizon 2020 grant from the EU.

The company’s stock (LIPUM) is traded on the Nasdaq First North Growth Market in Stockholm.